{"id":653087,"date":"2023-05-25T19:10:01","date_gmt":"2023-05-25T19:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=653087"},"modified":"2023-05-25T19:10:01","modified_gmt":"2023-05-25T19:10:01","slug":"chemotherapyinduced-peripheral-neuropathy-cipn-pipeline-assessment-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-medicinova-solasia-esteve-makscientific","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-peripheral-neuropathy-cipn-pipeline-assessment-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-medicinova-solasia-esteve-makscientific_653087.html","title":{"rendered":"Chemotherapy-induced Peripheral Neuropathy (CIPN) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MediciNova, Solasia, Esteve, MakScientific"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chemotherapy-induced Peripheral Neuropathy (CIPN) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MediciNova, Solasia, Esteve, MakScientific\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Chemotherapy-induced Peripheral Neuropathy (CIPN) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MediciNova, Solasia, Esteve, MakScientific\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy-induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Chemotherapy-induced Peripheral Neuropathy Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Chemotherapy-induced Peripheral Neuropathy Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Chemotherapy-induced Peripheral Neuropathy Pipeline report embraces in-depth commercial, regulatory, and Chemotherapy-induced Peripheral Neuropathy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the emerging Chemotherapy-induced Peripheral Neuropathy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Chemotherapy-induced Peripheral Neuropathy Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/1e28f82b84c004bc35664755788fa2b3.jpg\" alt=\"Chemotherapy-induced Peripheral Neuropathy Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Chemotherapy-induced Peripheral Neuropathy Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the <strong>emerging therapies for Chemotherapy-induced Peripheral Neuropathy treatment<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different<strong> Chemotherapy-induced Peripheral Neuropathy therapies<\/strong> segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major <strong>Chemotherapy-induced Peripheral Neuropathy companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the <strong>Chemotherapy-induced Peripheral Neuropathy drugs<\/strong> that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the <strong>Chemotherapy-induced Peripheral Neuropathy therapeutic market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Chemotherapy-Induced Peripheral Neuropathy Drugs by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration of the Emerging Chemotherapy-Induced Peripheral Neuropathy (CIPN) Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravitreal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subretinal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monoclonal Antibody<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptides<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Polymer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Chemotherapy-induced Peripheral Neuropathy Treatment Outlook will Evolve with the Ongoing Clinical &amp; Commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-induced Peripheral Neuropathy Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There are approx. 13+ key companies which are developing therapies for Chemotherapy-induced Peripheral Neuropathy (CIPN). Currently, MediciNova is leading the therapeutics market with its Chemotherapy-induced Peripheral Neuropathy (CIPN) drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-induced Peripheral Neuropathy Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">MediciNova<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Asahi Kasei Pharma Corp.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AnnJi Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EA Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Aptinyx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sonnet Biotherapeutics Holdings<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Toray<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Solasia Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Enveric Biosciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regenacy Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NeuroBo Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Chemotherapy-induced Peripheral Neuropathy Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">MN-166 (ibudilast): MediciNova<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ART-123: Asahi Kasei Pharma Corp.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SP-04 (PledOx): Solasia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">E-52862: Esteve<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AM 1710: MakScientific<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EQ-6: AxoProtego Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EA4017: EA Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BXQ-350: Bexion Pharmaceuticals, Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sodium selenite pentahydrate: Boryung Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Halneuron (Tetrodotoxin): WEX Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SON 080: Sonnet Biotherapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Chemotherapy-induced Peripheral Neuropathy Companies Working in the Market:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Chemotherapy-induced Peripheral Neuropathy Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Chemotherapy-induced Peripheral Neuropathy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Chemotherapy-induced Peripheral Neuropathy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Chemotherapy-induced Peripheral Neuropathy Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Chemotherapy-induced Peripheral Neuropathy Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Chemotherapy-induced Peripheral Neuropathy Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Chemotherapy-induced Peripheral Neuropathy Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Chemotherapy-induced Peripheral Neuropathy Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Chemotherapy-induced Peripheral Neuropathy Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Chemotherapy-induced Peripheral Neuropathy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Chemotherapy-induced Peripheral Neuropathy Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Chemotherapy-induced Peripheral Neuropathy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports by&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dental-lasers-market\">Dental Lasers Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;Dental Lasers Market Insight, Competitive Landscape, and Market Forecast, 2028&rdquo; report delivers an in-depth understanding of historical and forecasted Dental Lasers market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial &amp; regulatory development, in the Dental Lasers Market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chemotherapyinduced-peripheral-neuropathy-cipn-pipeline-assessment-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-medicinova-solasia-esteve-makscientific\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chemotherapyinduced-peripheral-neuropathy-cipn-pipeline-assessment-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-medicinova-solasia-esteve-makscientific\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy-induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-peripheral-neuropathy-cipn-pipeline-assessment-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-medicinova-solasia-esteve-makscientific_653087.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-653087","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=653087"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653087\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=653087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=653087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=653087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}